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Abstract 
GABAA receptor (GABAAR) function may be inhibitory or excitatory in the brain 
depending on the chloride electrochemical gradient over the neuronal membrane. 
This gradient is tightly regulated by cation-chloride transporter (CCC) 
expression 
Premature birth (PTB) occurs in 5-18% of pregnancies, however the mechanism 
behind PTB remains unknown. The progesterone metabolite, allopregnanolone 
(AP) inhibits uterine contractions and GABAAR sensitivity to APis increased 
by presence of the subunit. GABAAR  subunit expression and the presence of 
APmay therefore be contributing factors in premature birth.  
The hormones that regulate pregnancy have also been shown to regulate 
endometrial cancer. Analysis of GABAARs and CCCs expression patterns in 
endometrial cancer samples may indicate changes during pregnancy, 
contributing to premature birth. 
This study aimed to provide the first complete quantitative analysis of GABAAR 
and CCC gene expression in the uterus, and endometrial cancer and to develop 
an appropriate in vitro model to investigate the effects of AP on uterine cell 
function to further understand the functional role of GABAARs and CCCs in the 
uterus. 
Gene expression was analysed in healthy human uterus, endometrial cancer and 
APtreated COLO684 cells using qRT-PCR. COLO684 cells were used as an in 
vitro uterine model and treated with physiologically-relevant concentrations of 
AP. Protein expression was assessed by immunoblotting. 
GABAAR subunits and CCCs changed in expression when comparing healthy 
uterus to endometrial cancer data. The data from APtreated COLO684 cells 
indicated that the GABAAR  subunit was not expressed but other GABAAR 
subunits were. These results support the hypothesis that GABAARs and CCCs 
are present and possibly functional in the uterus, and that GABAARsubunit 
expression may be influenced by APwhich subsequently may indicate a role in 
preterm birth. 
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CHAPTER 1. Introduction  
1.1-aminobutyric acid (GABA)  
 
-aminobutyric acid (GABA) is an inhibitory amino acid neurotransmitter in the 
central nervous system (CNS). The synthesis of GABA occurs by decarboxylation 
of glutamate by glutamate decarboxylase (GAD), which relies on the cofactor 
pyridoxal 5’- phosphate (pyridoxal-P) for activity (Abdul et al., 2008, Wu et al., 
2014). GABA is released from the pre-synaptic nerve terminal and binds to the 
GABAA receptor (GABAAR) located at the postsynaptic membrane; any 
remaining unbound GABA is taken back up into the neurons by the Na+- and Cl- 
-dependent GABA transporter. GABA is then metabolised to succinic 
semialdehyde (SSA) by GABA transaminase (GABA-T) (Li and Xu, 2008). 
GAD67 and GAD65 (human isoforms of GAD) have been identified in the oviduct, 
indicating that GABA is produced by the reproductive system, supporting the 
hypothesis of the study that GABA and GABA receptors may have a regulatory 
role in uterine contractions (Fujii and Mellon, 2001). 
 
1.2 GABA receptor structure and function  
 
GABAA receptors (GABAARs) are pentameric channels composed of a variety of 
different subunits with receptor subtypes displaying diverse pharmacological and 
physiological properties (Bracamontes and Steinbach, 2008; Harvey et al., 1993). 
In mammals, there are 16 GABAAR subunits α1−6, β1−3, γ1−3, δ, ε, θ and π, 
which are classified depending on sequence homology (Bracamontes and 
Steinbach, 2008; Harvey et al., 1993).  The subunit transcripts can also undergo 
alternative splicing, which further increases diversity between receptor subtypes 
(Mehta and Ticku, 1999; Zafrakas et al., 2006). Each subunit is composed of an 
extracellular NH2 terminal domain (~200 amino acids) with four putative 
membrane-spanning domains, referred to as M1-M4 with a large, variable, 
cytoplasmic domain between M3 and M4 (Figure 1.1; Connor et al., 1998).   
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Figure 1.1 Schematic diagram of the GABAA subunit and receptor. The 
GABAA receptor subunit structure comprises an extracellular hydrophilic N-
terminal, which connects to the M1 transmembrane α-helixes (labelled 1-4). 
There is a large intracellular loop between M3 and M4. The M2 domains of each 
subunits form a ligand-gated ion (Cl-) channel lining. (B) The purple square (BZs) 
represents benzodiazepines binding site to the γ/δ. The GABA binding sites are 
represented by the grey triangle G on the GABAAR lie at the αβ interfaces. The 
image is extracted from (Gurba, 2010). 
 
The α and β subunits are essential for a normal functioning GABAAR; most 
receptors are typically composed of two α subunits and two β subunits. The α 
and β subunits can form functional receptors alone, however, more commonly, 
there is an additional  subunit. In fact, the  subunit is required to confer 
sensitivity to benzodiazepines (Connor et al., 1998). The  subunit can be 
substituted by other subunits, including δ, ε or π, however, this is less common 
(Connor et al., 1998, Harvey et al., 1993, Olson and Seighart, 2009). The π 
subunit has been shown to assemble with α, β and  subunits into a functional 
GABAAR in vitro (Neelands and Macdonald, 1999), although there is still more 
evidence needed for the existence in vivo of this assembly. The most abundant 
GABAAR subtypes found in the CNS are α, β, γ complexes, however, it should 
be noted that despite decades of research, only 11 receptor subtypes have been 
fully confirmed (Olsen and Sieghart, 2009). The expression of the different 
subunits not only dictates the receptor properties, but also the receptor 
localisation (Harvey et al., 1993).  The majority of the work focusses on GABAARs 
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in the brain; there is far less is known about the receptor subtypes outwith the 
brain. It is noteworthy that the π subunit is not present in the brain, but is found 
in the uterus. The benefit of having a receptor subtype not found in the brain is 
that it may be targeted with drugs without such severe side effects. 
1.3 GABAARs role in development central nervous system  
 
GABAARs are ligand-gated Cl- channels, with a primarily inhibitory function in the 
adult CNS. Their main role is regulation of neuronal excitability, elicited by 
glutamate. Opening of the central chloride channel occurs when two molecules 
of GABA simultaneously bind to the GABAAR, causing a change in conformation, 
which in turn opens the channel. Once the channel is open, the Cl- ions 
influx/efflux into or out of the cells depending upon the Cl- electrochemical 
gradient, thereby causing hyperpolarisation (chloride influx) or depolarisation 
(chloride efflux) of the cell (Owens et al., 1996). 
 
The receptors themselves are neither inhibitory nor excitatory, their function is 
dependent on the chloride electrochemical gradient, which influences the 
direction of chloride flux (Borodinsky et al., 2003, Ganguly et al., 2001).  This is 
determined by expression levels of CCCs. During early development, the 
intracellular concentration of chloride is higher than the extracellular 
concentration, therefore, activation of GABAARs causes excitation (Ben-Ari, 
2002). In the mature CNS (>3 weeks in mammals) the intracellular chloride 
concentration is much lower and activation of receptors elicits hyperpolarisation, 
an inhibitory response (Ben-Ari, 2002). This change in activity is referred to as 
the GABA or chloride switch (Figure 1.2).   In addition to the Cl- gradient changes, 
the expression of post-synaptic GABAAR subtype also undergo changes by 
replacing α3 containing GABAARs with α1 containing GABAARs in mature 
synapses. This is also dependent on the Cl- gradient (Succol et al, 2012). 
Therefore, the identification of the GABAARs and the CCCs expressed in the 
uterus could give a possible indication of the function of the GABAAR as well as 
the possibility of a GABA or chloride switch. 
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The intracellular concentration of Cl- is dependent on the expression of an 
importer or by the delayed expression of an exporter. Na+– K+– 2Cl– co-
transporters (NKCC1-2), which typically raise intracellular Cl– concentrations, and 
the K+–Cl– co-transporters (KCC1-4), which normally lower intracellular Cl– 
concentrations. In the brain, NKCC1 accumulates intracellular Cl- and is highly 
expressed during early development and is responsible for high intracellular Cl- 
concentrations (Succol et al., 2012).  At this stage, when GABA binds to the 
GABAAR, the Cl- channel opens leading to Cl- efflux, which depolarises the cell 
and, in turn, activates voltage-dependent calcium channels resulting in an 
increase of Ca2+ currents into the neuron thus causing further excitatory 
depolarisation (Figure 1.2) (Ben-Ari, 2002).  However, the expression of the Cl- 
exporter, KCC2 later in development has been shown to have a key role in the 
GABA switch from excitatory to inhibitory (Ben-Ari, 2002). It is hypothesised that 
KCC2 expression is self-limiting. GABA itself promotes the shift from excitation 
to inhibition (Ben-Ari, 2002).  When GABA binds to the GABAARs, the Cl- channel 
opens leading to Cl- influx, which in turn hyperpolarises the cell thus inhibiting 
voltage-dependent calcium channels resulting in a decrease of Ca2+ currents in 
to the neuron (Figure 1.2). The action of GABA has switched from excitatory to 
inhibitory (Ben-Ari, 2002).  
 
Understanding the possible expression of GABAARs, NKCCs, and KCCs in the 
uterus may help to determine if GABAARs are localised there and if they are 
excitiory or inhibitory in function.  Functional GABAARs within the uterus may 
therefore have a role in the regulation of myometrial contraction. 
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Figure 1.2 The change in the action of GABA during early development of 
the CNS.  The GABA switch is postulated due to the activity of the sodium, 
potassium coupled chloride co-transporter (NKCC1), which imports chloride into 
the cells. In developing neurons (left-hand side) there is high expression of 
NKCC1 transporters and low expression of potassium chloride co-transporters 
(KCC) type 2 (KCC2), which export chloride from cells. As development of the 
CNS progresses (right-hand side), NKCC1 expression is reduced and increased 
expression of KCC2 is seen, thereby changing the intracellular chloride 
concentration from high to low (Li and Xu, 2008). In line with the changes in CCC 
expression, GABA changes from eliciting a depolarising (excitatory) response in 
immature neurons to a hyperpolarising (inhibitory) response in mature neurons.  
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1.4 Cation chloride co-transporters 
 
The movement of ions across the membrane is controlled by channels and 
transporters. Cation chloride co-transporters (CCCs) are important in regulating 
the intracellular Cl- gradient. The CCC family is made up of nine members, which 
are encoded in the SLC12 gene family (Slc12a1-9) (Blaesse et al., 2009, Vardi 
et al., 2000). The CCC proteins are plasma membrane ion transporters, 
glycoproteins with a molecular weight range of 120-200 kDa (Blaesse et al., 
2009). CCC functions are divided into two groups: Na+– K+–2Cl– co-transporters 
(NKCCs) which has two members; NKCC1 and NKCC2, and K+– Cl– co-
transporters which has four members, KCC1-4 (Blaesse et al., 2009, Chen et al., 
2010, Vardi et al., 2000).  
 
NKCC1 and KCC2 are the isoforms predominantly found in the CNS and are 
therefore important in controlling the neuronal Cl- intracellular concentration 
(Rivera et al., 2005). NKCC1 accumulates Cl- in the neuron, whereas KCC2 
extrudes Cl- from the neuron (Delpire, 2000; Succol et al., 2012). The expression 
of these two CCCs relates directly to the function of GABAARs (Succol et al., 
2012). The expression of NKCC1 increases the depolarisation of the neuron, 
whereas the expression of KCC2 increases the hyperpolarisation of the neuron 
when the GABAARs are activated (Figure 1.2) (Rivera et al., 2005).  
 
NKCC1 expression is found in neurons in the CNS, and also in the periphery 
(Blaesse et al., 2009). The other CCCs have been identified out with the CNS. 
NKCC2 is abundantly expressed in the kidneys, and is a drug target for the 
diuretic, bumetanide (Blaesse et al., 2009). The transport of K+ and Cl- has a 
significant role in the homoeostasis of epithelial cells: KCC1, KCC3 and KCC4 
transporters occurs in response to cell swelling and change in pH. The KCC 
isoforms are co-expressed together; KCC1 is co-expressed with KCC3, while 
KCC2 is co-expressed with KCC4. Post-transcriptional modifications such as 
phosphorylation are essential for the activation of the KCCs (Blaesse et al., 2009, 
Chen et al., 2010).   
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The relationship between CCCs and GABAARs is important to note as the 
expression of CCCs influences function of the GABAAR, whether it be excitatory 
or inhibitory. Research by Succol et al. (2012) found that the post synaptic 
GABAAR subtypes change depending on whether the neuron is immature or 
mature. The change in subtype has been shown to be due to the Cl- gradient and 
the expression of KCC2. The work herein is focused on peripheral GABAAR and 
CCC expression. Identification of specific GABAAR subunits and CCCs 
expressed in the uterus, will help provide the first information towards potential 
receptor subtypes and their role in the uterus.   
 
1.5 GABA out with the CNS 
 
GABAARs are abundant in mammalian brains, but have also been identified in 
other regions outside the CNS (refer to table 1.1), including: uterus, placenta, 
peripheral nervous system, lungs, liver, ovary, small intestine, testis (Akinic and 
Schofield, 1999), pancreas (Johnson and Haun, 2005), endocrine cells of the 
pituitary, adrenal, and islets of Langerhans (Hedblom and Kirkness, 1997), and 
the palate (Ymer et al., 1989). Within endocrine cells, GABAARs are involved in 
the regulation of hormone secretion (Akinic and Schofield, 1999, Hedblom and 
Kirkness, 1997, Johnson and Haun, 2005, Ymer et al., 1989).   
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Table 1.1. Expression of GABAAR subunits outside the CNS. A survey of the 
literature was completed to identify the expression of GABAAR subunits in 
peripheral tissues. Documented gene expression is represented by +.  
 
The presence of GABAARs in the periphery is important to note as it indicates 
that GABAARs may not only be functional in the CNS. The identification of 
GABAARs in the uterus supports the hypothesis that these may have a functional 
role in uterine contractions. This study aimed to characterise the presence of 
potential GABAAR subtypes in the uterus (by investigating GABAAR subunit gene 
expression) while also helping to determine the function during the gestational 
period. This would help provide a novel drug target for modulation of myometrial 
contractions in premature birth. 
 
1.6 The mechanism behind labour 
1.6.1 Uterine contraction 
 
The smooth muscle layer of the uterus, the myometrium, is active throughout a 
women’s life, not just during labour (Pehlivanoglu et al., 2013). Uterine 
myometrium serves by contracting at the right time with exactly the desired force 
during labour and remaining relaxed during the period of pregnancy 
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(Pehlivanoglu et al., 2013). Some of the unwanted results of myometrial 
dysfunction are untimed contractions leading to preterm delivery, or stronger than 
necessary contractions causing foetal distress, hypoxia and even death of the 
foetus (Pehlivanoglu et al., 2013).  
 
Uterine contractions in pregnant women transforms from a silent, non-contracting 
state to an actively contracting organ for a successful delivery (Pehlivanoglu et 
al., 2013). This is achieved by morphological changes and adaptations under the 
effect of elevated oestrogen and progesterone and the balance between these 
two hormones (Pehlivanoglu et al., 2013). Uterine contractions are predominantly 
regulated by intracellular calcium concentration [Ca+2] (Pehlivanoglu et al., 2013). 
Irrespective of the triggering stimulus, [Ca+2] elevation is essential for contraction, 
which may either enter from the extracellular fluid into the cell across the surface 
membrane through voltage-gated L-type Ca+2 channels and/or be released from 
intracellular stores in the sarcoplasmic reticulum (SR) (Pehlivanoglu et al., 2013).  
 
During pregnancy the uterus is relaxed and the cervix remains closed and rigid 
(Garfield and Maner, 2007). However at term, the cervix softens and dilates while 
the uterus becomes contracted. Contractions occur in the myometrial cells and 
the depolarisation of the uterus muscles is due to inward current Na+ ions 
(Garfield and Maner, 2007). This leads to activation of voltage gated L- type 
channels which causes increased intracellular concentration of Ca2+. Myosin light 
chain kinase is then activated by Ca2+-calmodulin (Garfield and Maner, 2007). 
The activation results in phosphorylation of myosin and contraction of the uterus.  
Once contraction occurs, the uterus relaxes and this is a direct result of the 
extraction of intracellular Ca2+ by the Na-Ca exchanger and Ca2+-ATPase 
(Garfield and Maner, 2007). The sarcoplasmic reticulum is also involved in the 
removal of intracellular Ca2+ resulting in hyperpolarisation of the cells causing 
relaxation of the uterus (Garfield and Maner, 2007). 
 
Extracellular signal regulated kinase (ERK) plays a role in the regulation of uterine 
contractions (Xiao et al., 2002). The activation of the ERK pathway is dependent 
on dual phosphorylation of Ser and Thr by mitogen activated/ extracellular-
regulated kinase (MEK) (Xiao et al., 2002). Pregnancy has been shown to 
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increase the ERK signalling in a1-adrenoceptor-mediated contractions (Xiao et 
al., 2002). The identification of the ERK pathway in the uterus and the active role 
in contractions supports the hypothesis that GABAARs may be involved in the 
uterine contraction via activation of the ERK pathway (see Figure 1.4). 
 
Uterine contractions occur in the smooth muscle of the myometrium. When 
stimulated too early during the gestation period, the cells become depolarised, 
which can lead to preterm labour.  As previously mentioned, the GABAARs 
function is dependent on the Cl- intracellular concentration. We hypothesise that 
the GABAARs in the uterus may therefore have a role in the regulation of 
myometrial contraction. Identification of the characteristics of the GABAARs in the 
uterus may show potential for a new drug to help prevent premature birth.  
 
1.7 Premature birth  
 
Birth before the 37th week of gestation is defined as premature birth (PTB). It 
occurs in 5-18% of births worldwide (Liong et al., 2013) and is the leading cause 
of neonatal death or disabilities, such as respiratory disorders, blindness and 
deafness (Henge et al., 2014, Challis et al, 2000,). The precise cause of PTB 
remains unknown, however, it has been proposed that approximately 30% of PTB 
is due to underlying infections (Challis et al., 2002). Premature rupture of the 
foetal membranes also occurs in 1 in 3 cases (Sundrani et al., 2012). To date, 
there is still no useful biomarker available to predict women with preterm 
premature rupture of membranes and PTB (Liong et al., 2013). Currently, two 
diagnostic tests that are used to predict women at risk of PTB.  However, these 
diagnostic tests have limitations as they rely on the abnormal presence of foetal 
fibronectin or phosphorylated insulin-like growth factor binding protein 1 in the 
cervicovaginal fluid (Liong et al., 2013). The foetal fibronectin (fFN) test is the less 
accurate of the two as the test has been known to give false positives due to 
unprotected sexual intercourse (Liong et al., 2013).  In both tests the biomarkers 
give low positive values in predicting premature birth. Therefore, the use of these 
tests has had little impact on the premature birth rates (Liong et al., 2013). 
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1.7.1 Therapeutic intervention in premature birth  
 
The main treatment available to women with previous premature births is the 
administration of 17α-hydroxyprogesterone caproate. The drug relaxes the 
uterus by inhibiting contractions and acts by binding to progesterone receptors or 
glucocorticoid receptors (Hines et al., 2013). However, 17α-hydroxyprogesterone 
caproate binds to these receptors with a lower affinity than progesterone and 
glucocorticoids (Hines et al., 2013). Therefore, the drug may not function fully; 
however, the exact mechanism of action of 17α-hydroxyprogesterone caproate 
is still poorly understood (Hines et al., 2013). Muscimol (a GABAAR agonist) is 
another drug administered to inhibit uterine contractibility (Putnam et al., 1991). 
Other interventions to prevent preterm labour include cervical stitching and 
cervical pessary (Abdel-Aleem et al., 2013; Alfirevic et al., 2013). However, these 
treatments are not fully effective and have limitations.  
 
Due to the lack of information surrounding the mechanisms of premature birth 
(PTB), the identification of potential biomarkers or treatments remains 
challenging. A clear understanding of the role of GABAARs (and CCCs) in preterm 
labour may offer a novel perspective on this under-researched area. It is 
important to understand the mechanism of preterm labour not only due to the 
effects on the infant but also burden on health care around the world. 
 
1.8 Pregnancy regulation and hormone production 
 
The normal human gestation period is approximately nine months (40 weeks). In 
the last six decades the endocrine system has been shown to play a functional 
role in regulation of the myometrium during gestation period (Hill et al., 2010). 
The production of steroid hormones varies at different stages of the pregnancy, 
however the main role of steroid hormones during gestation are involved in 
regulation of uterine contractions (Hill et al., 2010).  
 
The progesterone metabolite of particular interest; allopregnanole (5α derivate), 
has a role in the regulation of pregnancy by binding to GABAARs (Byrns, 2014; 
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Hill et al., 2001; Figure 1.5).  The enzyme 5α reductase type 1 catalyses the 
conversion of progesterone to 5 α dihydroprogesterone (5α DHP) the precursor 
for the formation of allopregnanole (3α-hyroxy 5α−pregnan 20 one (APα)) (Figure 
1.3) (Byrns, 2014; Hill et al, 2001).   The activation of chloride channels, such as 
GABAARs and CCCs, by steroid hormones or GABA, could cause chloride efflux 
causing the cells to become depolarised and therefore increase contractions. 
This study aimed to look at the changes in gene expression when subjected to 
APα.  
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Figure 1.3 Steroid hormone synthesis from the precursor pregnenolone. 
Enzymes involved in producing progesterone and the metabolites APα and 
pregnanolone. Adaptation from Byrns (2014), Hill et al. (2001) and Parizek et al. 
(2005).   
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1.9 Allopregnanole in pregnancy 
 
APα is a neurosteriod found in the CNS (Wang et al., 2005). APα binds with high 
affinity to the GABAARs (Wang et al., 2005). In mature neurons, APα is an 
allosteric modulator, which binds to GABAARs resulting in increased chloride 
influx, causing hyperpolarisation which in turn decreases neuronal excitability 
(Wang et al., 2005).  However, in immature neurons the action of APα has the 
opposite effect. The exact binding site or sites for APα is still unknown.  
 
The main source of APα in women is the corpus luteum and the adrenal cortex 
(Ottander et al., 2005; Timby et al., 2006). During the menstrual cycle, serum 
APα concentrations are approximately 0.5 nmole/L, but rise in the mid luteal 
phase to 4-5 nmole/L (Luisi et al., 2000). However, during pregnancy, 
fetoplacental synthesis causes maternal APα serum levels to rise more than 10 
times the maximum menstrual cycle levels (Beverley et al., 2001; Parizek et al., 
2005), while falling to 20-30 nmol/L at the time of labour (Hill et al., 2001) and 
dropping to 2 nmol/L after delivery.  
 
1.9.1 Uterine GABAARs and the potential role of APα 
 
Of particular interest is the robust expression of GABAA receptor subunit genes 
in mammalian uterus (Fujii and Mellon., 2001, Hedblom and Kirkness, 1997, 
Putnam et al., 1991). Several subunits (α1, α2, β3, δ and π) were identified in rat 
uteri by end-point polymerase chain reaction (PCR) (Fujii and Mellon., 2001). 
Interestingly, the expression of these different subunits fluctuated over the 
gestational period (Fujii and Mellon, 2001), although the analysis completed was 
only semi-quantitative at best. The proposed function of the receptors is 
suggested to be the inhibition of uterine contraction via binding of the 
progesterone metabolite APα, (Fujii and Mellon, 2001, Hedblom and Kirkness, 
1997).  
 
APα is a much more potent inhibitor of uterine contractions than its precursor 
progesterone, and acts by binding specifically to GABAARs. Increased sensitivity 
19 
 
to APα was found in GABAARs that contained α1 and π subunits when compared 
to GABAARs comprising α2 and δ subunits (Fujii and Mellon, 2001) however, 
other studies have found δ subunits to increase GABAARs sensitivity to APα. 
however, previous research is incomplete as it only analyses a small subset of 
receptor subunits and the assembly of a native uterine GABAARs has not been 
fully elucidated. There is a particular paucity of information relating to the π 
subunit (as it is not expressed in mammalian brain). However, due to the strong 
expression in uterus, the ability to bind APα, and the unique pharmacological 
properties it may confer to the receptor, it is an interesting area of investigation 
in the field of pregnancy and preterm labour. 
 
1.9.2 Sulphated APα hormones in pregnancy and their role on GABAARs 
 
During pregnancy, APα becomes sulphated (Park-Chung et al., 1999). The 
addition of the sulphate group at the 3 alpha hydroxyl group of the APα, changes 
the modulation of GABAARs from positive to negative (Beverley et al., 2001; 
Parizek et al., 2005; Park-Chung et al., 1999). The identification of sulphated 
forms of the steroid hormones and the effect they have on GABAARs is important 
to note as this may help to indicate the function GABAARs have during pregnancy 
and labour. This was beyond the scope of the current study and requires further 
investigation into the possible change in GABAARs function. 
 
 
1.10 The link between endometrial cancer and pregnancy 
 
 
Evidence in endometrial cancer indicates that steroid hormones are involved in 
the progression of the cancer, with high levels of estrogen and insufficient levels 
of progesterone being detected (Julie Kim and Chapman-Davis, 2010). The 
changes in estrogen and progesterone levels in endometrial cancer are similar to 
those found at the time of labour as progesterone falls and estrogen levels rise 
(Kim and Chapman-Davis, 2010). In this study we were unable to obtain human 
pregnancy samples, however we used human endometrial cancer samples to 
help determine if the GABAAR subunits and CCCs change expression pattern 
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depending on the change in physiological conditions when compared to healthy 
human uterus.  
 
On a side note to the study the current literature to date shows that GABAARs 
are involved in cancer proliferation and cell invasion, however the GABAAR 
subunits have never been identified in endometrial cancer. We also took this 
opportunity to identify the possible GABAAR subunits expression in endometrial 
cancer as the exact characterisation and function is still unknown.  
 
 
1.11 Cancer 
 
Cancer is characterised by the ability of cells to sustain chronic proliferation. 
Normal tissues and organs carefully control the production and secretion of 
growth promoting signals, which contribute to cell growth and division (Hanahan 
and Weinberg, 2011). However, cancer cells do not regulate the growth 
promoting signals which bind to cell receptors (Hanahan and Weinberg, 2011). 
These signals activate signaling cascades, which result in cell proliferation and 
uncontrolled growth (Hanahan and Weinberg, 2011).   
 
It is predicted that there will be 22.2 million new cases of cancer by 2030 (Lee et 
al., 2014). The five most frequently occurring cancers are lung, breast, 
colorectum, stomach and prostate (Lee et al., 2014). Cancer represents a broad 
group of pathophysiology, typically occurring with uncontrolled multiplication of 
cells, this forms the primary tumour. Metastasis (secondary tumorigenesis) is, 
however, independent of the initial proliferative activity (Lee et al., 2014). The 
overall progression of cancers is strongly based on epigenetic, chemical and 
physical factors (Lee et al., 2014).  
 
Inflammation triggers cell division and damage to DNA as a result of the 
increased production of free radicals (Hanahan and Weinberg, 2011, Mondugno 
et al., 2005). These are thought to introduce somatic mutations, which have been 
identified in the P13K/Akt and Erk/MAPK signaling pathways (Hanahan and 
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Weinberg, 2011, Mondugno et al., 2005). Cancers have been associated with 
increased replication errors and ineffective DNA repair of key regulatory genes, 
especially tumour suppressor genes. Inflammatory cytokines induce a variety of 
inflammatory enzymes, which contribute to the formation of prostaglandin which 
stimulates factors that have characteristics of activating cell migration and 
proliferation (Modugno et al., 2005). 
 
1.11.1 Metastases 
 
The life-threatening aspect of cancer is metastasis. This is defined by the tumour 
cells detaching from the primary tumour, invading the stromal tissue, entering the 
bloodstream or lymphatic system and migrating around the body (Lee et al, 
2014). The cancer cells, which are able to survive, either remain dormant or form 
secondary tumours in the targeted organs such as liver, brain, lung and bones 
(Lee et al, 2014). The development of metastasis is dependent on the interactions 
between cancer cells and stroma (Lee et al., 2014).  
 
Cancers that metastasise are shown to have poor prognosis. This has been 
shown in liver and pancreas cancer due to a change in GABA signaling, which 
dysregulates the MAPK pathway (Young and Bordey 2009).  The regulation of 
the cell cycle through GABA and glutamate signaling may contribute to cancer 
survival (Neman et al., 2013). A study by Miao et al. (2010) found that treatment 
with propofol, a commonly used intravenous anaesthetic agent, can directly 
activate GABAAR channels. The study concluded that propofol may inhibit cancer 
cell invasions due to the decrease in MMP production as a result of GABAAR 
pathways MAPKs and ERK1/2 deactivation.  
 
1.12 Endometrial Cancer 
 
Endometrial cancer (EC) is a gynaecological malignancy, the sixth most 
commonly diagnosed cancer.  There are approximately 288,000 new cases and 
50,327 deaths annually (Subramaniam et al., 2013).  Incidence and mortality 
rates of EC are rising in developing counties and are predicted to rise further with 
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ageing and obesity (Subramaniam et al., 2013).  Between 20 % and 25% of cases 
are diagnosed pre-menopause, of which 5% are before the age of 40 (Yamazawa 
et al., 2007). Cancer that occurs at a younger age is related to estrogen exposure 
through hormone disorders (Yamazawa et al., 2007). 
 
Uterine cancer has two main types: uterine sarcomas, which usually arise from 
the myometrium (smooth muscle) or endometrial stromal sarcomas and 
leiomyosarcomas which arise from the supporting connective tissue of the uterus 
(Yamazawa et al., 2007).   
 
Endometrial carcinomas originate in the cells of the endometrium (inner lining) 
and these are the most common types of uterine cancer. Most endometrial 
cancers are known to be adenocarcinomas, malignant tumours formed from the 
epithelial tissue glandular structures (Sadeghi and Taylor, 2010).  The COL684 
cell line are human uterus adenocarcinoma, and were used in this study to 
analyse the change in GABAAR and CCC gene expression in the presence of 
APα, and various GABAAR and CCC agonists and antagonists. 
 
1.13 GABA and Endometrial Cancer 
 
GABA and GABAARs have been identified in a variety of cancers, including 
prostate, breast, colon, gastric, ovarian and pancreatic cancers (Abdul et al., 
2008, Roberts et al., 2009 Wu et al., 2014, Young and Bordey, 2009, Zhang et 
al., 2013).   In these cancers, dysregulation in the GABAergic system occurs 
resulting in increased GAD enzyme and GABA, which, in turn increases cell 
proliferation. This occurs as a result of activation of the Erk1/2 MAP kinase and 
PI3K, signaling pathways (Figure 1.5) (Abdul et al., 2008, Roberts et al., 2009 
Wu et al 2014., Young and Bordey, 2009, Zhang et al.,2013).   
 
 
The GABAAR π subunit gene has also been identified in uterine tissue, (Fujii and 
Mellon, 2001; Symmans et al., 2005). The APα levels are also thought to be 
associated with π subunit expression (Symmans et al., 2005). APα in the brain 
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binds to the GABAAR which triggers expression of genes that support the cell 
cycle (Wang et al., 2005) as well as activating the ERK/MAP kinase (MAPK) 
pathway, although this however has still to be identified in EC (Wang et al., 2005). 
EC treatment is still limited, and the standard therapy used today for EC is a full 
hysterectomy as well as the removal of the ovaries. These therapies are invasive 
and not ideal if the patient is young, though hormonal therapy has been used in 
such cases to avoid surgery (Senna et al., 2005: Yamazawa et al., 2007).  
However, there are still concerns as to which therapy is the optimal one to use in 
EC.  
 
 
 
 
 
Figure 1.5 MAPK and PI3K pathways in cancer cells. MAPK and PI3K 
pathways have shown to contribute to cancer cell proliferation. The pathways are 
also involved in the regulation of gene expression and migration. The pathways 
are triggered by excitatory GABAergic activity, which leads to the influx of Ca2+ 
and the activation of the small guanine nucleotide binding to Ras. This  activates 
Raf followed by the mitogen – activated ERK- activating kinase (MEK) refer to 
Figure 1.5 (Bell–Horner et al., 2006). 
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The PI3k/Akt signaling pathway is activated in parallel to the ERK/MAP kinase 
(MAPK) pathway (Davies and Samuels 2010, Xie et al., 2004). The P13K /Akt 
pathway has also been associated with cell proliferation and cell growth along 
with migration (Figure 1.5); these pathways have been identified in several 
cancers (Jiang and Liu, 2009). The activation of the PI3k/Akt signaling and 
ERK/MAP kinase (MAPK) pathway may be due to the GABAARs activation, 
supporting the idea that these pathways and GABAAR may be involved in uterine 
cancer. While the GABAARs may change from an inhibitory role to excitatory role 
depending on the intracellular Cl- concentration.   
 
GABAARs have been previously identified in uterine cancer. Reverse 
transcriptase PCR has identified moderate expression of the α3 subunit in 
endometrial cancer (Liu et al., 2009). The GABAAR is believed to activate the 
PI3K/Akt and ERK/MAPK signaling pathways (Subramaniam et al., 2013). These 
pathways are involved in regulating the GABAAR, gene transcription as well as 
cell proliferation and cell survival (Subramaniam et al., 2013). The pathways can 
also be activated by the GABAAR which are activated by the phosphorylation of 
the α subunit of the receptor (Subramaniam et al., 2013). Identification of these 
pathways show promise in identifying GABAAR in EC. 
 
1.14 CCCs and cancer 
 
The role of CCCs has become of interest in terms of tumour invasion, cell 
proliferation and migration. Cancer cells have shown to have more active 
proliferation, migration as well as mitosis (Hanahan and Weinberg., 2011).  Up-
regulation of KCC1, KCC3 and KCC4 gene expression occurs during cervical 
carcinogenesis (Chen et al., 2010).  Studies have identified a relationship 
between insulin like growth factor 1 (IGF-1) and KCC activity in cervical, ovarian 
and breast cancer (Chen et al., 2010). The KCC activity is linked to the 
phosphophatidylinostiol 3-kinase (PI3K) and extracellular signal–regulated 
kinase-1/2 (Erk1/2) MAP kinase signaling pathways (Chen et al., 2010).  The 
increased KCC3 and KCC4 expression in these cancers have a physiological role 
in cell proliferation, invasion and metastasis (Chen et al., 2010). The expression 
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of KCC in cervical cancer cells gives rise to the hypothesis that KCC are present 
in the uterus and in endometrial cancer. This however, requires further study. The 
link between CCCs and GABAA receptors has not been well researched in 
cancer.  
 
1.15 GABAAR Therapeutics 
1.15.1 Traditional GABAAR therapeutics 
 
GABAARs are drug targets for several pharmacologically important drugs. The 
assembly of the different subunits determines the pharmacology of the individual 
receptor (Olsen and Sieghart, 2009).  The configuration of the GABAAR results 
in five binding sites available on the receptor surface: two binding sites are 
present at α, β region, which form the GABA binding site (Figure 1.1; Olsen and 
Sieghart, 2009). The binding site present at the α/γ subunit interface on the 
receptor is bound by benzodiazepines (Figure 1.1). Benzodiazepines are a class 
of drug clinically used as muscle relaxants, anxioytics, hypnotic agents and 
anticonvulsants (Weizman et al., 1997). The sensitivity to different 
benzodiazepines is dependent upon the type of α and γ subunits present within 
the receptor (Olsen and Sieghart, 2009). There are different forms of 
benzodiazepines, such as diazepam and flunitrazepam, and these drugs have 
been shown to activate GABAAR subtypes, α1βγ2, α2βγ2, α3βγ2 or α5βγ2, but 
show no activity with the subtypes, which contain α4βγ2 or α6βγ2 (Olsen and 
Sieghart, 2009).  Imidazobenzodiazepines, flumazenil, or Ro15-4513 interact 
with the receptor subtypes, which contain α4βγ2 or α6βγ2. When 
benzodiazepines bind to GABAARs they produce a sedative effect. Other positive 
and negative allosteric drugs such as barbiturates, neuroactive steroids, propofol 
and picrotoxin have shown to act through GABAARs and their sensitivity and 
activity is dependent on the GABAAR subtype (Olsen and Sieghart, 2009; 
Watanabe et al., 2000 and Wu et al., 2014).  These drugs are used to treat many 
anxiety disorders, however, the properties of these agents may help to prevent 
premature birth due to their ability to allow muscle relaxation (Weizman et al., 
1997).  
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Neelands and Macdonald (1999) found that GABAAR subtype expressing the 
 configuration formed a functional GABAAR with different 
pharmacological properties from those GABAAR expressing and . 
The GABAAR expressing  showed no sensitivity to benzodiazepines 
however did have increased sensitivity to loreclezole an anticonvulsant drug. 
Lareclezole may therefore have the potential to help prevent premature births 
depending on the GABAAR expressed. The change in pharmacological properties 
of the GABAAR in which is expressed helps support the hypothesis of the study 
that characterising non-classical GABAAR, π-containing GABA conduction in the 
periphery could provide a novel drug target for modulation of myometrial 
contractions. 
 
1.16 GABAAR therapeutics and cancer 
 
Patients who suffer from cancer pain are provided with a wide range of 
pharmacological therapies, which include non-opioid analgesics, acetaminophen 
and non-steroidal anti-inflammatory drugs (Lee et al., 2014). When looking at 
treatment for cancer pain, Benzodiazepines, such as Valium, enhance 
GABAergic signaling. Gabapentin is known as a GABA mimetic which is 
commonly prescribed to cancer patients to reduce neuropathic and postoperative 
pain. Gabapentin acts mainly on the 2 subunit configuration of the GABAARs 
(Lee et al., 2014). 
 
GABA and GABAARs are therapeutic targets in cancer pain patients, however 
research has shown that some tumour characteristics, such as uncontrolled 
proliferation, can be induced by GABA, and this is apparent in a variety of cancers 
(Lee et al., 2014). 
 
The GABAAR pathways such as MAPK pathways have shown promising 
therapeutic targets inhibiting the pathway to prevent tumour growth (Serra et al., 
2013). PI3K inhibitors reduce cell proliferation (Serra et al., 2013), however 
further study is needed to identify the least toxic combinations for inhibiting MAPK 
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pathways. MEK-PI3K inhibitors have also shown promising effects on certain 
tumours (Serra et al., 2013). 
 
GABAAR agonists and antagonists have been tested in cancer such as colon, 
lung and pancreatic carcinoma cells however only propofol had an effect on the 
different colon cancer cells as it may inhibit cancer cell invasion (Miao et al., 2010) 
while also decreasing the production of MMPs production due to the deactivation 
of the GABAAR MAPKs pathway. Although there is limited research on effect of 
GABAAR drugs in cancer, propofol shows potential and may be developed into a 
specific cancer anesthetic especially in uterine cancer if GABAARs are identified 
(Miao et al., 2010). 
 
1.17 Hypothesis: The potential role of GABAARs in prevention and 
treatment of pre-term labour 
 
Uterine contractions occur in the smooth muscles of the myometrium and are 
regulated by the balance between the two steroid hormones estrogen and 
progesterone. The intracellular calcium concentration [Ca+2] also has an effect on 
regulating uterine contractions. When the myometrium is stimulated too early 
during the gestation period, the cells become depolarised, which can lead to 
preterm labour.  
 
GABAA receptors have been shown to have an inhibitory response during 
gestation, however in preterm labour, we hypothesise that a change in GABAAR 
subtype and function in the uterus may play a role in induction of preterm 
contraction. To determine the actual subtype of GABAARs and CCCs in the 
uterus, healthy and endometrial cancer samples were used, this was due to two 
reason: 1) the similar physlogical condtions found in both pregnantant and 
miligant uteri. 2) many studies of GABAARs in the periphery have been done in 
cancer samples. Functional GABAARs within the uterus may therefore have a 
role in the regulation of myometrial contraction. Due to the wide range of possible 
GABAA receptor subtypes within the CNS, characterising non-classical, π-
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containing GABA conduction in the periphery could provide a novel drug target 
for modulation of myometrial contractions. 
1.18 Aims of research study 
 
Identification of potential GABAAR subtypes and characterisation of GABAergic 
and CCC receptor expression in mammalian uterus will further understanding of 
the functional role of GABAARs in the uterus. This study aimed to provide the first 
complete analysis of GABAAR and CCC gene expression in uterus, fully quantify 
gene expression changes during gestation and develop an appropriate in vitro 
model to analyse the effect of allopregnanole in uterine cells. This novel 
information forms a strong basis to conduct further research into the functionality 
of uterine GABAARs and their role in pre-term labour. As a complementary side-
line to the work, the expression of GABAARs and CCCs in uterine cancer was 
conducted, providing further evidence of the existence, and importance, of 
GABAA receptors in mammalian uterus.  
 
The individual aims of this project were:  
1) To analyse GABAAR and CCC gene expression at RNA and protein level 
in human healthy uterus and human endometrial cancer samples using 
quantitative polymerase chain reaction (qPCR) and immunoblotting. 
2) To analyse GABAAR and CCC gene expression in non-pregnant vs. 
pregnant uterine tissue from sheep. 
3) To quantitatively analyse selected GABAAR subunit genes and CCC 
genes in mouse uteri at nine different time points during gestation. 
4) Development of an in vitro model using an appropriate cell line (COLO684) 
to analyse GABAAR and CCCs expression and functionality in the 
presence of allopregnanalone, and various GABAAR and CCC agonists 
and antagonists. 
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CHAPTER 2. Materials and Methods  
 
2.1 Diethyl pyrocarbonate (DEPC)-treated water preparation 
 
DEPC-treated water was prepared to remove DNase and RNase activity from 
dH2O in preparation for gene analysis. The DEPC-treated water contained a final 
concentration 0.001% (V/V) DEPC in a total volume of 1L. Once prepared, the 
solution was incubated for 24 h at room temperature and autoclaved at 121oC to 
inactivate the DEPC. Unless specified, all work involving RNA used water treated 
in this way.   
 
2.2 COLO684 cell culture  
 
The COL684 cell line (human uterus adenocarcinoma; HPA culture collections, 
Salisbury, UK) was available at the laboratory at passage 2. COLO684 cells were 
grown in suspension in Roswell Park Memorial Institute (RPMI) 1640 media 
without L-glutamine (GE, healthcare, UK), supplemented with 10% (v/v) foetal 
bovine serum (FBS), 1% (v/v) penicillin streptomycin and 2 mM L- glutamine (Life 
technologiesTM, Paisley, UK), and incubated in an atmosphere of 5% CO2, at 
37°C.  
 
Cells were counted by diluting 1:2 with Trypan blue (Sigma-Aldrich, Poole, UK), 
where 10 μL was added to a haemocytometer and the cells were counted using 
the central square representing 1x 104 cell/ mL.  Once the cells had reached 3-9 
x 106 cell/ mL, they were passaged at a ratio of 1:10. Cells were centrifuged at 
110 x g for 5 minutes at room temperature, the old media was removed and the 
cells re-suspended in fresh media. COLO684 cells were seeded in a T75 flask in 
a 1:10 dilution of fresh RPMI every 48 h. 
 
Cell freezing solution was prepared with a 1:5 dilution of FBS and dimethyl 
sulfoxide (DMSO). COLO684 cell stocks was prepared by freezing 500 μL of cell 
suspension with 1 mL freezing solution and 1 mL media, cells were transferred 
to cyrotubes and placed in a Mr. Frosty freezing container with isopropanol 
(Nalgene®, UK) at -80oC before being transferred to liquid nitrogen storage. 
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COLO684 cell were revived by adding 1 mL media to the cells before transferring 
to a falcon tube. The cells were centrifuged at 110 x g for 5 minutes at room 
temperature, the old media was removed and the cells resuspended in fresh 
media. 
 
2.3 Treating COLO684 cells with allopregnanalone.  
 
An in vitro model using uterine cells treated with allopregnanalone (AP) was 
established to determine the effects on GABAAR subunit and CCC gene 
expression. For the preliminary assay, cells were counted as described in section 
2.2. The COLO684 cells were seeded at 1 x 106 cell/ mL in a T25 flask in 5 mL 
RPMI 1640 without L-glutamine and grown for 24 h at 37oC. After 24 h, cells were 
treated with a range of concentrations of AP, 0-150 nM (Tocris Bioscience, UK). 
AP was prepared to a final concentration of 10 mM in dimethyl sulfoxide 
(DMSO).  Intermediate AP stocks were prepared at 0-150 μM in DMSO and 5 
μL of AP intermediate stock was added to cells in 5 mL of media to give a 1:1000 
dilution and a final contraction of 0-150 nM AP. Cells were also treated with 
DMSO only to a final concentration of 0.01% (V/V) as a vehicle control. COLO684 
cells were treated for 24 h and re-dosed at 48 h and 72 h. After each exposure, 
the cells were harvested as previously described in section 2.3. Samples were 
stored at -80oC until further analysis. 
 
2.3.1 Analysing cell viability by Alamar blue. 
  
Cell viability was analysed by Alamar assay to determine the effects of the range 
of allopregnanalone concentrations and the vehicle control DMSO on COLO684 
cells. The cells were counted as described in section 2.2, seeded at a density of 
5x 102 cell/ mL per well in a 96-well plate in a volume of 200 μL media and 
incubated for 1 h at 37oC. The cells were treated in triplicate with a range of 
concentrations 0-100 nM of AP (Tocris Bioscience, UK). AP stocks were 
prepared at 0, 50 nM, 500 nM and 1 μM in media, 20 μL of AP intermediate 
stock were added to cells in 200 μL of media to give a 1:10 dilution and a final 
contraction of 0-100 nM AP. Cells were also treated with DMSO only to a final 
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concentration of 0.01% (V/V) as drug vehicle control. Alamar blue ® (Invitrogen, 
UK) was added 24 h before the plate reading, 10 μL of Alamar blue ® was added 
to each treatment in triplicate except for the media only control. COLO684 cells 
were treated for 24 h, 48 h and 72 h.  The data was acquired on a 96 plate reader 
LT-50000MS ELISA READER (Thermo scientific, Waltham Massachusetts, 
USA), the blank reading at 600 nm wavelength was subtracted from all readings 
and the data was expressed as a percentage of the untreated control. 
 
2.4 Harvesting COLO684 cells 
 
COLO684 cells were harvested by transferring the cells from the plate into a 
sterile microfuge tube then centrifuged at 110 x g for 5 minutes at room 
temperature. The media was discarded and the cell pellet was washed by 
resuspension in 1 mL phosphate- buffered saline (PBS) and transferred into a 
sterile 1.5 mL microfuge tube. The suspension was centrifuged for 5 minutes at 
800 x g, at 4oC, the PBS was removed and the pellet left to dry and stored at -
80oC for subsequent RNA or protein extraction.  
 
2.5 RNA extraction  
 
RNA was extracted from COLO684 cells in preparation for complementary 
(c)DNA synthesis and quantitative polymerase chain reaction (qRT-PCR) 
analysis. After the cells were harvested, 1 mL of TRI Reagent® solution 
(Ambion™, UK) was added to the cell pellet, and the lysate passed several times 
through the pipette tip. The samples were incubated for 5 minutes at room 
temperature before 0.2 mL of chloroform was added per 1 mL of TRI Reagent® 
solution and mixed by inversion for 15 seconds. Samples were incubated at room 
temperature for 3 minutes followed by centrifugation at 12000 x g for 15 minutes 
at 4oC. The aqueous phase was removed and transferred to a sterile microfuge 
tube and the RNA was precipitated from solution by adding 0.5 mL cold isopropyl 
alcohol. Samples were incubated for a further 30 minutes on ice before they were 
centrifuged at 12000 x g for 10 minutes at 4oC. The supernatant was removed 
and the RNA pellet washed with 1 mL 75% (v/v) ethanol and vortexed. Pellets 
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were centrifuged at 7000 x g for 5 minutes at 4oC, then left to air dry. The RNA 
pellet was resuspended in 20 μL of DEPC-treated water and stored at -80oC. 
 
2.5.1 Commercial RNA samples 
 
Commercially-available matched RNA from healthy human uterus and human 
endometrial cancer were obtained from AMSBio®, Abingdon, UK. Healthy human 
brain RNA was also obtained from (AMSBio®, Abingdon, UK) and was from a 65-
year-old female. Pregnant whole mouse uterus RNA was obtained from AMSBio, 
(Abingdon, UK) and stored at -80oC until use. The pregnant mouse RNA was 
extracted from nine different gestation period time points (E10-E18), which 
correspond to the Theiler stages 16-26 of the embryo. 
 
2.5.2 Analysis of RNA integrity by agarose gel electrophoresis 
 
RNA integrity was analysed on 1% (w/v) agarose gel in (Tris- acetate- EDTA) 
TAE buffer (0.01 M Ethylenediaminetetraacetic acid (EDTA), 0.4 M Tri acetate 
EDTA-Trizma and Acetric acid). Once heated, 4 μL of Safeview (NBS Biologicals 
Ltd, UK) was added. The gel was placed in the Bio-rad mini-sub cell gt® tanks 
(Bio-Rad, California, USA). RNA samples were diluted 1:15 with DEPC-treated 
water to a final concentration of 90 nM/ μL and loading buffer (4x LSB (20% (w/v) 
glycerol, 200 mM Tris pH 6.8, 4% (w/v) SDS, 10 mM EDTA, 1% (w/v) 
bromophenol blue supplemented with 10% (v/v) -mercaptoethanol) was added, 
and 15 μL of diluted RNA was added to each well. Samples were electrophoresed 
at 80 V for 1 h in TAE buffer. The gel was then analysed using the Biorad 
molecular imager ChemidocTM   xrs+ (California, USA) and an image was taken 
with Image labTM software. The hyperladderTM (Bioline, UK) was used to indicate 
the size, all RNA underwent bioanalyser analysis. 
 
2.6 Bioanalyser analysis  
 
The quality and quantity of each RNA sample was further analysed by use of the 
Agilent Bioanalyzer (Agilent Technologies Ltd, UK). The gel matrix was prepared 
using the provided gel matrix (Agilent RNA 6000 Nano Kit, Catalogue number 
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5067-1511), which was filtered by centrifugation for 10 minutes at 1500 x g, 65 
μL was aliquoted into RNase-free microfuge tubes. Following this, 1 μL of RNA 
dye concentrate (Agilent, Catalogue number 5067-1511) was added to the 65 μL 
filtered gel matrix and vortexed. The gel-dye mix was centrifuged for 10 minutes 
at 13000 x g at room temperature. A RNA 6000 Nano chip was placed on the 
priming station and 9 μL of gel-dye mix was placed into allocated wells. In every 
well, 5 μL of RNA marker (Agilent, Catalogue number 5067-1511) was added. 
For sample analysis, 1 μL of diluted RNA ranging from 20 ng to 500 ng was added 
to the wells. Any unused wells were filled with 1 μL of RNA marker. The chip was 
placed on the IKA vortex (Agilent Technologies Ltd, UK) for 1 minute at 534 RCF 
and analysed on the Agilent 2100 Bioanalyser.  Only RNA samples with an RNA 
integrity number (RIN) of above 7.5 were used for further gene expression 
analyses (Bustin et al., 2009). 
 
2.7 DNase treatment of pregnant mouse uterus RNA samples 
 
The commercial mouse uterine RNA samples showed evidence of DNA 
contamination, subsequently, they were subjected to DNase treatment. The 
DNase digestion reaction mix contained 2 μg each RNA, in 1x final concentration 
of RQ1 reaction buffer, 1 unit/μg RNA RQ1 RNase-Free DNase (Promega) and 
DEPC-treated water in a final volume of 10 μL. Samples were incubated for 30 
minutes at 37oC. The reaction was terminated by the addition of 1 μL of DQ1 
DNase stop solution. Once the stop solution was added the samples were then 
incubated at 65oC for 10 minutes to inactivate the DNase, and stored at -800C for 
future use. Prior to storage, RNAs were reanalyzed using the Bioanalyzer to verify 
removal of DNA contaminants. 
 
2.8 Complementary (c)DNA synthesis 
 
Reverse transcription was used to convert RNA extracted from the treated COLO 
684 cells and commercial RNA into cDNA to allow amplification during 
quantitative polymerase chain reaction (qRT-PCR). Firstly, 20 μL of reverse 
transcription premix 2,oligonucleotides used were random Nonamer and OligoDT 
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mix (PrimerDesign™, Southampton, UK), was dispensed into thin-walled reaction 
tubes and 2 μg RNA was added. The samples were placed into a thermocycler 
set at 42oC for 20 minutes followed by 10 minutes of incubation at 72oC. cDNA 
samples were diluted with DEPC-treated water to 5 ng/μL and stored at -20oC. A 
non-reverse transcriptase (Non RT) control was prepared for each cDNA using 
the Precision Nanoscript™2 reverse transcription kit 
(PrimerDesign™,Southampton, UK).  
 
2.9 Oligonucleotides used in this study 
 
Specific qRT-PCR oligonucleotides were designed to amplify cDNAs encoding  
GABAARs subunit transcripts, namely,  1-3,  1-3, and  the 
chloride cotransporters (NKCC1-2 and KCC1-4) from both human and mouse. 
The majority of oligonucleotides were designed previously by other researchers 
in the lab. The sequences of oligonucleotides targeting human CCC transcripts 
are given in Table 2.1 and oligonucleotides to amplify GABAAR subunit 
transcripts in Table 2.2. The mouse CCC transcript oligonucleotides are shown 
in Table 2.3 and oligonucleotides towards GABAARs subunits in table 2.4. 
Housekeeping gene oligonucleotides were purchased commercially (GeNorm, 
PrimerDesignTM, UK). Details of the oligonucleotides used in this study can be 
found in Table 2.3, 2.4, 2.5 and 2.6. Each oligonucleotide was designed to cross 
exon boundaries, either in the oligonucleotide sequence or in the amplicon, to 
prevent amplification of genomic DNA. Oligonucleotides were designed with a 
melting temperature (Tm) of 58-61oC and a GC content of 40-60%. All 
oligonucleotides were subjected to Basic Local Alignment Search Tool (BLAST) 
analyses to ensure specificity (Nation Center for Biotechnology information, 
https://www.ncbi.nlm.nih.gov).  
 
Oligonucleotides were synthesised by Eurofins MWG Biotech (Germany) and 
resuspended in the appropriate volume of DEPC-treated water outlined by the 
manufacturer to give a final concentration of 100 pmol/ μL. All oligonucleotides 
were stored at -20oC until use. Oligonucleotides were validated by BLAST 
35 
 
analysis along with analysis of the Melt curves to ensure one amplicon and the 
use of a negative control. 
 
Table 2.1. Oligonucleotides sequences towards human cation chloride co-
transporter (CCC) transcripts. Forward and complementary oligonucleotide 
sequences, amplicon size, melting temperature (Tm) and relevant NCBI 
accession number are shown.   
 
  
Target 
Sequence 
5’ to 3’ 
Ampl
icon 
(bp) 
Tm 
(oC) 
Accession 
number 
NKCC1 
F- TTATTAAAGGAACATTCAAGCACAG 
92 
69.5 
NM_001046 
R-  GCCATGTAGAGAGCACTAGAC 55.9 
NKCC2 
F- GTTATAGTCAGAATCAGCCAAGGA 
130 
57 
NM_000338 
R- TTTCCTCTTCACACTCATTATCTTTG 57 
KCC1 
F- AATGAAGTCATTGTCACGCGC 
207 
57 
NM_020708 
R- GCCACAAGATGACACTGGG 58 
KCC2 
F- AGCGTTCCCAGATCCTCAAA 
177 
57 NM_001134
771 R- GCGTGTTGGCTGGATTCTT 56.5 
KCC3 
F-TGTTCCCTTTGCTTGCTTCA 
115 
56.2 
NM_133647 
R- GGAGTTGTAAATAATGCTTCTACCA 56.3 
KCC4 
F-  TACGGAAGTTTCTAGGCCCG 
165 
58 NM_00658.
2 R- TCACTGGCTTCTTGTGACCTG 59 
36 
 
Table 2.2. Oligonucleotides sequences towards human GABAAR subunit 
transcripts and reference genes. Forward and complementary oligonucleotide 
sequences, amplicon size, melting temperature (Tm) and relevant NCBI 
accession number are shown.   
Target 
Sequence 
5’ to 3’ 
Am
plic
on 
(bp) 
Tm 
(oC) 
Accession 
number 
GABRA1 
F- ATCTTCAGCAAAGGAGCACG 
243 
56 NM_00080
6.5 R- AAAGACAGTCAGACAGACCTG 57 
GABRA2 
F- CTGATTCAGTACAGGTTGCTCC 
94 
59 NM_00080
7.2 R- ACTGGATTTAATTGTCTCCTTTCCG 59 
GABRA3 
F- TTGGGAAGGCAAGAAGGTGC 
130 
55 NM_00080
8 R- AGTGTCCTTGGCCAGGTTG 58 
GABRA4 
F- TGCGGAGTGTCCCATGAGA 
98 
58 NM_00080
9.3 R- CTAAGCTGGAAGACTCCTTCG 59 
GABRA5 
F- TGAAATTTGGCAGCTATGCGTAC 
168 
58 NM_00081
0 R- TGTATTCGCCTGTGCTGGTG 58 
GABRA6 
F-CAGGACATAATCTAAGACCSCAAC 
127 
56.8 NM_00081
1 R- TGCCTCAAGTCAGTAATCCAATAG 57.3 
GABRB1 
F- AGGATATGACATTCGCTTGCGG 
136 
59 NM_00081
2.3 R- AGACTGCTGGAAATACATGGTGAG 60 
GABRB2 
F- TTAAAGAGACGGTGGATAGACTC 
98 
58 NM_02191
1.2 R- AATGTCAATGTTCATCCCCACAG 58 
GABRB3 
F- CATATTTCATAAGCACTCCAACTACT 
110 
57.4 NM_00081
4.5 R- TTGCCTCAGAGAACGGTCAT 57 
GABRG1 
F- CATGGATGAACATTCCTGTCCAC 
183 
60 NM_17353
6.3 R- TAATCCCCAGAGATCGTGTGAG 59 
GABRG2 
F- ACAGGAAGCTCAGTCTACTCG 
116 
59 NM_19890
4.2 R- TCATAGTCATCATCAGATTTCTGGC 59 
GABRG3 
F- TCCTCAAGATGGATTCCTGAGC 
153 
59 NM_03322
3.4 R- ATCCAGACACTCATAGACACAGG 60 
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Table 2.2.continued: 
 
Target 
Sequence 
5’ to 3’ 
Ampl
icon 
(bp) 
Tm 
(oC) 
Accession 
number 
GABRP 
F-TGCATTGGAGTGACGACCG 
175 
59 NM_01421
1 R- GCTGTAAGGAACTGTAGTGAGC 59 
GABRD 
F- CGACTACAGGAAGAAGCAGAAG 
92 
57 NM_00081
5.4 R- AGAGGGAGAAGAGGACAATGG 56.8 
GABRE 
F-TTCTGAATGGCAATGTGGTGAGCC 
179 
59 NM_00496
1.3 R-TTGATACGAGGATGGCGGAGTTTAG 60 
GABRQ 
F-TGGTAGAGAGCTATGGTTACACG 
129 
59 NM_01855
8.3 R-TAGACATACTCCAGCAAGGACAG 59 
EIF2B1 
F- TATACGTCACAGAGTCACAGCC 
106 
59 NM_00141
4.3 R- TAGCCGACAGCAGCATCTAGC 61 
 
Table 2.3.  Oligonucleotides sequences towards mouse chloride co-transporter 
(CCC) transcripts. Forward and complementary oligonucleotide sequences, 
amplicon size, melting temperature (Tm) and relevant NCBI accession number 
are shown. 
Target 
Sequence 
5’ to 3’ 
Amplic
on 
(bp) 
Tm 
(oC) 
Accession  
number 
NKCC1 
F- TGTGGGTTCGTGTGTTGTTCGG 
144 
61 NM_009194
.3 R- ATTAGCCCGTAAGAACAAGTATTGC 59 
NKCC2 
F-TTCATTGGAACTGTCATCCCATCC 
128 
60 NM_183354
.2 R- AAGACCGAGAAGAAGCCTTCCC 61 
KCC1 
F-TCATCTGCTGCTGCTGTACCC 
156 
61 NM_001253
804.1 R- TCGTCCCCAGGTAGAAGCAC 60 
KCC2 
F- TGCTGGCTTATCTCTTCCCAG 
145 
59 NM_020333
.2 R- TACTTGACACCCACAAAGACAACG 60 
KCC3 
F- CTGGCCTGTGTAATTGTGTCG 
154 
59 NM_133648
.2 R- TTGTCAACCTCCTTGGTCTTAGAG 60 
KCC4 
F- GTCAAATATGTCAACAAGCTGGCAC 
163 
60 NM_011390
.2 R- CACAGGTATCAAAGTTGCGATTTGC 60 
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Table 2.4. Oligonucleotides sequences towards mouse GABAAR subunit genes 
of interest and housekeepers. Forward and complementary oligonucleotide 
sequences, amplicon size, melting temperature (Tm) and relevant accession 
number are shown.  
Target 
Sequence 
5’ to 3’ 
Amplic
on 
(bp) 
Tm 
(oC) 
Accession 
number 
GABRA1 
F- AAGAAGCTATGGACAGCCCTCC 
181 
61 NM_01025
0.5 R- ATCGTGGTCTGAAACTGGTCCG 61 
GABRA2 
F- ATGCCCACTGAAATTTGGAAGCTAC 
88 
60 NM_00806
6.3 R- AACCTGAACGGAGTCAGAAGC 59 
GABRA3 
F- TAGCCAAGGGGAATCAAGACG 
91 
59 NM_00806
7.4 R- AGGAATATCTGGGGCATGCTTGG 52 
GABRA4 
F- AAGGACGAGAAATTGTGCCCG 
162 
59 NM_01025
1.2 
 
R- TTCCATTTCAACATCAGAAACGGGC 60 
GABRA5 
F-AGAGCGAATCACGCAGGTGC 
162 
60 NM_17694
2.4 
 
R- AGGTTGTTGAGAGGGAGGCG 60 
GABRA6 
F- CAGGACATAATCTAAGACCSCAAC 
127 
56.8 NM_00081
1 R- TGCCTCAAGTCAGTAATCCAATAG 57.3 
GABRB1 
F- TCTATGGACTACGGATCACAACC 
132 
60 NM_00806
9.4 R-TCCAGTAAAATTCGATGTCATCCGTG 59 
GABRB2 
F- GCTTTGTCTTCGTCTTTATGGCC 
146 
60 NM_00807
0.3 R- CATCTTGTTGACATCCAGGCG 59 
GABRB3 
F- ATCGGGTACTTCATTCTTCAGACG 
125 
60 NM_00807
1.3 R- AGCACGGTGGTAATCCCAAGG 61 
GABRG1 
F- CATGGATGAACATTCCTGTCCAC 
183 
60 NM_17353
6.3 R- TAATCCCCAGAGATCGTGTGAG 59 
GABRG2 
F- ACAGGAAGCTCAGTCTACTCG 
116 
59 NM_19890
4.2 R-TCATAGTCATCATCAGATTTCTGGC 59 
GABRG3 
F- TCCTCAAGATGGATTCCTGAGC 
153 
59 NM_03322
3.4 R- ATCCAGACACTCATAGACACAGG 59 
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Table 2.4. Continued: 
 
Target Sequence 
5’ to 3’ 
Amplic
on 
(bp) 
Tm 
(oC) 
Accession 
number 
GABRP 
F-TTCTGGAAACCTATGTCCCTTCC 
100 
61 NM_146017.
3 R- ACTCCAATGCAGGTTCTCGCAG 61 
YWHAZ 
F- ATCCTGAACTCCCCAGGAAAGC 
178 
61 NM_011740.
3 R- CTGCTTCTGCTTCATCTCCTTGG 61 
TOP1 
F- ATGGTAAAGTTATGAAGCTGAGTCC 
196 
59 NM_009408.
2 R- TACTGGCTCATCTGTGTAAAGTCG 60 
CYC1 
F- TTGGACCACACCAGCATTCG 
125 
58 NM_025567.
2 R- TTGGCTTCTTCCTCCGTGTAG 59 
 
2.10 Quantitative polymerase chain reaction (qPCR) 
 
qPCR was employed to profile GABAAR subunit and CCC gene expression in 
healthy human uterus, endometrial cancer, pregnant mouse uterine tissues and 
COLO684 cells. 
 
The PrimerDesign™ PrecisionPLUSTM Master mix gene detection kit was used. 
Each reaction contained, a final concentration of 6 pmol forward and reverse 
oligonucleotide, 25 ng cDNA template, DEPC-treated water and 10 μL 
precisionPLUS/ PrecisionFast to give final volume of 20 μL. Positive controls to 
test the oligonucleotide specificity and reaction conditions included human or 
mouse/rat brain cDNA. Each reaction was completed in triplicate wells alongside 
a non-RT and no-template negative control. The samples were prepared on 
BrightWhite 96 well plates (PrimerDesignTM, UK) and sealed with MicroAmp™ 
optical adhesive film (Applied Biosystems,UK) . Amplification and quantification 
was carried out on the Step One Plus™ (Applied Biosystems,UK), thermocycler 
conditions were set at initial denaturation 95oC for 10 minutes followed by 40 
cycles of 15 seconds at 95oC and 1 minute at 60oC. The one melt curve cycle 
was set to 95oC for 15 seconds 60oC for seconds followed by a further 95oC for 
15 seconds. 
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After each reaction, a melt curve was conducted at 60oC increasing to 95oC with 
0.3oC increment with a final 15 second hold step to verify oligonucleotide 
specificity and to confirm amplification of a single product of the amplified 
transcript. The qPCRs were all analysed on Step One Plus Applied Biosystems 
machine (Foster City, United states).  
 
Before analysis of the genes of interest, a GeNorm experiment was completed to 
identify suitable reference genes for the individual experiments. The genes 
involved in this analysis were: BM2, YWHAZ, EFI4A2, TOP1, BIRF2, CYC1, 
SDHA, UBC, ATP5, EIFRAZ, RPLIZA, 18S, GAPDH, (available on the Primer 
Design website) EIF2B1 was also designed as a uterus specific reference gene 
(Almeida et al., 2014). The oligonucleotides were resuspended in 220 μL 
following the primer design protocol. These samples were prepared in the same 
way as The PrimerDesign™ PrecisionPLUSTM Master mix. 
 
The qRT-PCR data was analysed by using the 2ΔΔ method (Pfaffl, 2004) and data 
was analysed using SPSS for statistical significance using a three way repeated 
measures ANOVA and Tukey post hoc analysis (Livak and Schmittgen, 2001).  
 
2.11 Analysis of protein expression in COLO684 cells 
 
Following cell harvest, total protein was extracted from AP-treated COLO684 
cells in preparation for immunoblotting analysis of GABAAR  subunit and CCC 
protein expression. The extraction buffer comprised (50 mM Tris pH8, 150 mM 
NaCl, 1 mM EDTA, 1% (w/v) Triton X and 1% (v/v)) halt protease inhibitor cocktail 
(Thermo Scientific, UK). The volume of the cell pellet was estimated and 
approximately 3x the pellet volume of ice cold lysis buffer was added to each 
pellet. The pellet was thoroughly resuspended by pipetting and lysed by 
incubating on ice for 30 minutes. Lysate was clarified by centrifugation at 16000 
x g for 5 minutes at 4oC in benchtop centrifuge. The supernatant was transferred 
into sterile 1.5 ml microfuge tubes and stored at -80oC until further analysis. 
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2.11.1 Protein quantification  
 
A Bradford assay was carried out to determine the extracted protein 
concentration from the treated COLO684 cells. Protein samples (1 μL) were 
diluted 1:5 in dH2O and mixed with 200 μL of Bradford reagent (100 mg/ L 
Coomassie blue G250, 95% (v/v) ethanol, 85% (w/v) H3PO4) and added in 
triplicate to a 96-well plate. Stock bovine serum albumin (BSA) was prepared in 
dH2O to a final concentration of 10 mg/ mL BSA standards were prepared by 
diluting the stock in dH2O to final concentrations of 0.15, 0.25, 0.5, 0.75, 1.0 and 
1.5 mg/ml and 1 µL of each standard was added per well, in triplicate. The plate 
was incubated at room temperature for 5 minutes. The absorbance at 595 nm 
was measured using the LT-50000MS ELISA READER (Thermo scientific, 
Waltham Massachusetts, USA) and the protein concentration was calculated 
from the standard curve generated from the BSA concentration standards.  
 
2.11.2 Sample preparation 
 
Protein samples were prepared to a final concentration of 1 μg/ μL in 4 x loading 
sample buffer (20% (v/v) glycerol, 200 mM Tris pH 6.8, 4% (w/v) sodium dodecyl 
sulfate (SDS), 10 mM EDTA bromophenol blue, 100 μL-mercaptoethanol). 
Protein samples were heated at 95oC using a heat block for 5 minutes then 
cooled on ice before being loaded onto the sodium dodecyl sulphate - 
polyacrylamide gel (SDS-PAGE).
 
2.11.3 Sodium dodecyl sulphate - polyacrylamide gel electrophoresis 
(SDS-PAGE) 
 
SDS-PAGE was performed following the method of Laemmli (1970) using the 
Biorad mini-PROTEAN® Tetra system (Bio Rad, UK). The resolving gel consisted 
of 12% (w/v) acrylamide, 375 mM Tris pH 8.8, 0.1% (w/v) SDS, dH2O and 0.08% 
(w/v) ammonium peroxidosulphate. The stacking gel consisted of 5.1% (w/v) 
acrylamide, 0.125 M Tris pH 6.8, 0.1% (w/v) SDS, dH2O and 0.12% (w/v) 
ammonium peroxidosulphate. The gels were polymerised by the addition of 5 μL 
N,N,N’,N’,-tetranethyl-ethylenediamine (TEMED) to the resolving gel and 10 μL 
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added to the stacking gel. Samples were electrophoresed at 185 V for 50 minutes 
in running buffer (25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS, pH 8.3), and 
compared to the PageRule™ Prestained protein ladder (Thermo Scientific USA),  
 
2.11.4 Immunoblotting  
 
Immunoblotting analysis was carried out to analyse expression of the GABAAR 
-subunit and the CCCs at protein level in response to allopregnanalone 
treatment. Following SDS-PAGE, proteins were transferred onto nitro-cellulose 
membrane (GE healthcare, life sciences, Amersham, UK) by electrophoresis 
using the BioRad mini-PROTEAN® Tetra system. The electrophoresis was 
conducted in transfer buffer (25 mM Tris, 192 mM glycine, 20 % methanol) with 
an ice pack to prevent overheating, at 100 V for 1 hour, following the method of 
Towbin et al., (1979).  
 
In order to check equal loading and even transfer, membranes were stained with 
India ink. Ink stain was prepared with a 1:2 dilution of Indian ink in dH2O and 
membranes were stained at room temperature for 10 minutes with gentle shaking 
(50 rpm). The membrane was then washed with dH2O and blocked with 5% (w/v) 
dried milk powder in phosphate buffered saline Tween 20 (PBS-T, 0.05M 
phosphate buffer, 0.0135 M potassium chloride, 0.685 M sodium chloride, 1 mL 
Tween 20) for 1 hour at room temperature with gentle shaking (50 rpm). After 
blocking, the primary antibody (rabbitpolycolonal ab26055 (Abcam, UK),  
actin ( C-11) goat polyclonal (Santa Cruz Biotechnology,INC, Germany), NKCC1 
(C-14: c-21547) goat polyclonal (Santa Cruz Biotechnology,INC, Germany), 
KCC3  rabbit polyclonal (Abgent, INC, San Diego, USA) and KCC4  rabbit 
polyclonal (Abgent, INC, San Diego, USA)  were diluted 1:1000 and 1:200 
respectively in 5% (w/v) Marvel milk powder, added to the membrane and 
incubated overnight at 4oC. Primary antibody was removed and membrane was 
washed with 3 x 5 minute washes in PBS-T, secondary antibody (Goat anti rabbit 
and donkey anti goat, Odyssey, LI-COR® Biosciences, UK) were diluted in 
1:10000 in PBS-T plus 0.01% (w/v) SDS, was incubated with the membrane for 
45 minutes at room temperature while protected from light. After another 3 x 5-
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minute washes in PBS-T the membrane was analysed on the Odyssey® Li-cor 
(Cambridge, UK) using the programme Image studio version 2.0.  
 
2.12 Statistical analyses 
 
ANOVA and Tukey post hoc statistical analysis were performed on quantified 
data, and P<0.05 was set as the level of significance.   
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Chapter 3. Results 
 
3.1 Analysis of GABAAR gene expression in healthy human uterus 
 
The main aim of this study was to identify the potential presence of the GABAARs 
and CCCs in healthy human uterus by investigating gene expression.  The 
expression was initially analysed using qRT-PCR. Current research suggests that 
the GABAA receptor π subunit is highly expressed in the uterus (Fujii and Mellon, 
2001) and in order to form a functional receptor, other subunits must also 
associate with the  subunit. This study wanted to examine whether the GABAA 
receptor  subunit potentially forms a GABAAR in the uterus and subsequently, if 
there may be different GABAARs subtype present in the uterus compared to the 
CNS (which does not express -containing receptors).   
For the first time, this study quantified complete GABAAR subunit expression in 
healthy human uterus (n=2, refer to Table 3.1). The first sample of healthy uterus 
was analysed and the data showed moderate expression of the GABAAR 2 and 
3 subunits, weak expression of 4 and 5 subunits and interestingly, 1 and 6 
subunit transcripts were not detected. When analysing beta subunit gene 
expression, the β1 and β3 subunit genes were well expressed; although the β2 
subunit was detected, this was at a much lower level (Table 3.1).  The GABAAR 
gamma subunit genes also displayed varying levels of expression in human 
uterus with the 1 subunit having higher expression when compared to the 2 and 
3 subunit genes.  The study indicated robust expression of the  subunit in the 
healthy human uterus. 
After the initial findings, the second sample of healthy human uterus was 
analysed for confirmation of GABAAR subunit expression. The data from the 
second sample of healthy uterus showed similar findings, with the alpha subunit 
genes, moderate expression of the α2 and α3 subunit genes and weak 
expression of the α4 and α5 subunits. Again, the α1 and α6 subunit transcripts 
were not detected (Table 3.1). The data does however differ when comparing the 
beta and gamma subunits. β1 and β2 were undetected and β3 showed weak 
expression. The γ subunits data appeared to show low levels of γ3 whilst γ1 and 
γ2 were undetected. The different isoforms differ with the expression level and 
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pattern between the two uterine samples however, interestingly, both samples 
showed high expression of the π subunit gene (refer to Table 3.1). Expression of 
the GABAA  subunit gene was also analysed in healthy uterus, however it was 
not detected; ε and θ were not detected. The primary data shows that the 
GABAAR subunit genes are expressed in the uterus. The combination of receptor 
subunits expressed differs from that of the CNS (Bracamontes and Steinbach, 
2008) with π being highly expressed, potentially indicating different GABAAR 
receptor subtypes may be present in the uterus. 
3.2 Analysis of GABAAR gene expression in human endometrial cancer 
 
As GABAAR subunit gene expression was identified in healthy human uterine 
tissue, the study then analysed the possible changes in gene expression of 
GABAAR subunits in endometrial cancer using qRT-PCR. The two case studies 
were used for confirmation of gene expression. Within both of the endometrial 
cancer samples the results showed variation in gene expression (refer to Table 
3.1). Within both endometrial cancer samples the GABAAR α subunits were 
varied with the exception of α2 which was expressed in both endometrial cancers 
as well as human healthy uterus. 1 and 6 were not detected in endometrial 
cancer or in human healthy uterus. GABAAR subunits 4, 5 were detected in 
healthy uterus but not both of the endometrial cancer samples (Refer to Table 
3.1). Interestingly α3 expression appear to vary, the expression is noted in 
healthy human uterus and in the first endometrial cancer sample, however the 
expression was not detected in the second sample of endometrial cancer 
disagreeing with the Liu et al. (2009) study. When analysing the β subunit genes 
the data shows expression of 2 and 3 in both endometrial samples, however 
in sample 2 2 was not expressed in healthy uterus.  GABAAR subunit 1 
expression was not detected in both endometrial cancer but was detected in 
sample 1 healthy human uterus although, not in sample 2 of healthy human 
uterus.  The most variation between the GABAAR subunits was detected within 
the  subunits, in sample 1 of healthy human uterus all  subunits were expressed 
when compared to endometrial cancer only 3 was expressed. However in 
sample 2 healthy human uterus only 3 was expressed, andwere 
undetected, the expression patter changed in sample 2 of endometrial cancer as 
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the only  subunit not detected was 3. The  subunit gene was expressed in 
human healthy uterus as well as uterine cancer. In human brain the  subunit is 
not expressed, but is documented to be expressed in smooth muscle tissue (Fujii 
and Mellon, 2001). The data herein correlates with these findings. The ε and θ 
subunit genes were also studied however, no expression was detected in both 
endometrial cancers.  
In summary, when comparing both endometrial cancer samples, there was a 
variation in GABAAR subunit gene expression patterns. In the endometrial  
cancer samples the consistent GABAARs were 2, 2 and 3 and  (refer to 
Table 3.2). The data indicate the presence of GABAARs in uterine cancer, the 
subunit gene expression was different to that of healthy uterus, indicating a 
possible change in expression, which may play a role in endometrial cancer. The 
differences in subunit gene expression between the two cancer samples may be 
due to the natural heterogeneity of cancer between different patients (Hanahan 
and Weinberg, 2011).  
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Table 3.1. Analysis of expression of selected GABAAR subunit genes in 
two healthy human uterus and matched endometrial cancer samples 
Expression of GABAAR subunit genes was assessed by qRT-PCR and 
normalised to expression of the housekeeper gene, EIF2B1. Relative levels of 
expression in healthy uterus are represented by +: low; ++: relative; +++: strong; 
ND: not detected. Arrows represent an increase (↑) or decrease (↓) in gene 
expression in uterine cancer relative to healthy uterus. 
 
 
GABAAR 
subunit 
Gene expression 
(Sample one)  
Gene expression 
(Sample two) 
Healthy Cancer Healthy Cancer 
 ND ↓ ND ↓ 
 ++ ↑ ++ ↑ 
 ++ ↑ ++ ↓ 
 + ↓ + ↓ 
 + ↓ + ↓ 
 ND ↓ ND ↓ 
 ++ ↓ ND ↓ 
 +  ↑ ND ↑ 
 ++ ↑ + ↑ 
 ++ ↓ ND ↑ 
 + ↓ ND ↑ 
 + ↑ + ↓ 
 +++ ↑ +++ ↑ 
 ND ↓ ND ↓ 
 ND ↓ ND ↓ 
 ND ↓ ND ↓ 
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3.3 Analysis of CCCs gene expression in healthy human uterus 
 
Current studies show that the expression of chloride co-transporter (CCC) have 
a direct effect on GABAA R function (Ben-Ari, 2002).  Therefore, gene expression 
of the CCC family members was also investigated in healthy uterus using qRT-
PCR, the two healthy human uterus samples analysed in this study showed the 
same CCC gene expression profiles. The NKCC1 transcript had the highest 
expression in both samples of heathy uterus (refer to Table 3.2) and KCC4 gene 
expression was moderate when compared to NKCC1. The other CCCs, KCC1 
and KCC3 both had weak expression (refer to Table 3.2).  In both samples, 
transcripts encoding NKCC2 or KCC2 were not detected; this was anticipated as 
both are tissue specific to the brain and kidney respectively (Blaesse et al., 2009; 
Delpire, 2000). 
 
3.4 Analysis of CCC gene expression in endometrial cancer 
 
Once CCC gene expression had been established in healthy tissue, further 
analysis was undertaken to investigate the possible changes in gene expression 
in endometrial cancer. The CCC expression in both batches of endometrial 
cancer had the same expression profile (refer to Table 3.2), although 
interestingly, the expression pattern does not differ from healthy uterus. NKCC1, 
KCC1, KCC3 and KCC4 were all expressed in healthy and in both endometrial 
cancer samples.  
This data show that selected CCC genes were expressed in human uterus in both 
healthy and cancerous samples. Overall there appeared to be an increase in 
CCC expression in endometrial cancer. The expression of CCCs in the uterus, 
which is different to that in the CNS, supports the hypothesis that the CCC gene 
expression could influence the function of the GABAARs in the uterus. The 
correlation in change in gene expression between GABAARs and CCC has been 
shown in the developing CNS.  
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Table 3.2. Analysis of expression of selected CCCs genes in two healthy 
human uterus and matched endometrial cancer samples Expression of CCC 
targets was assessed by qRT-PCR and normalised to expression of the 
housekeeper gene, EIF2B1. Relative levels of expression in healthy uterus are 
represented by +: low; ++: relative; +++: strong; ND: not detected. Arrows 
represent an increase (↑) or decrease (↓) in gene expression in uterine cancer 
relative to healthy uterus. 
 
 
3.5 Protein expression of the GABAAR subunit in healthy human uterus 
and endometrial cancer 
 
Once robust GABAAR subunit gene expression was found in healthy and 
endometrial cancer, the next stage was to identify whether it was possible to 
detect the  subunit at the protein level. Immunoblotting was performed to 
analyse the protein expression in healthy uterus and endometrial cancer.  The 
immunoblot results were compared to actin.  Expression of the GABAAR 
subunit polypeptide in healthy uterine tissue was not detectable as no band 
could be observed at 50 kDa; the molecular weight of the  protein.  Whilst in 
endometrial cancer,  subunit protein expression was apparent with a high 
intensity band appearing at 50 kDa (refer to Figure 3.1). Interestingly, this did not 
correlate with the mRNA data, which indicated expression in both healthy and 
endometrial cancer samples.  
CCC 
Target  
Gene expression 
(Sample one)  
Gene expression 
(Sample two) 
Healthy Cancer Healthy Cancer 
NKCC1 +++ ↑ +++ ↑ 
NKCC2 ND ↓ ND ↓ 
KCC1 + ↑ + ↑ 
KCC2 ND ↓ ND ↓ 
KCC3 + ↑ + ↑ 
KCC4 ++ ↑ ++ ↑ 
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Figure 3.1 Protein expression of the GABAAR subunit in human healthy 
uterus and endometrial cancer.  A: Immunoblot showing  subunit polypeptide 
expression human endometrial cancer. B: 12% Immunoblot of the control -actin. 
3.6 Alamar blue toxicity assay for allopregnanalone (APα) treatment on 
COL684 cells 
 
The research to date has shown APcan alter GABAAR subunit expression and 
only receptors comprising the  subunit are sensitive to AP (Fujii and Mellon., 
2001, Hedblom and Kirkness, 1997). This work identified the presence of 
GABAAR subunits, notably the  subunit, and CCCs in the uterus, therefore, the 
next step was to investigate the effect of APα in the uterus. An in vitro model was 
developed using COLO684 cells to analyse the effect of APα on gene and protein 
expression of GABAAR subunits and CCCs. Initially, an Alamar Blue assay was 
performed to determine if the concentrations and the exposure times of the 
vehicle DMSO and APα were toxic to the cells (refer to Figure 3.2). Statistical 
analysis was performed and no statistical significance between the different 
concentrations and exposure time were observed. This therefore showed that 
exposure to APα was not toxic to COLO684 cells. 
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Figure 3.2 Analysis of potential APα toxicity via Alamar blue. Cells were 
incubated with 5 nM, 50 nM and 100 nM concentrations of AP for 24, 48 and 72 
hours. Absorbance was read at 595 nm wavelength and normalized to 600 nm.  
Untreated cells were taken to be 100 % viable and data was expressed as a 
percentage of untreated cells; n=3  
24 h 48 h 72 h 
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3.7 The effects of APtreatment on expression in COLO684 cells 
 
AP is a metabolite of progesterone, which, has an important functional role in 
inhibiting uterine contractions during the gestational period. During the gestation 
period, APfluctuates depending on the stage of gestation (Hill et al., 2001). The 
study aimed to analyse the effect of physiological concentrations of AP on the 
 subunit protein level, as several studies have indicated the  subunit affects the 
sensitivity of GABAARs to APduring pregnancy (Fujii and Mellon, 2001). In 
particular, AP levels found in the uterus of premenstrual women (2 nM), 
menstruation cycle (5 nM), third trimester (75 nM, and 150 nM), pre labour (50 
nM) and labour (25 nM) were examined  Beverley et al., 2001; Luisi et al, 2000; 
Hill et al., 2001and Parizek et al., 2005). 
 
The initial assay was developed by treating COLO684 cells with 
APconcentrations of 2 nM, 5 nM, 25 nM, 50 nM, 75 nM, 100 nM, 150 nM and 
200 nM. Immunoblotting was then performed to analyse  subunit protein 
expression. The initial assay data showed that GABAARsubunit was expressed 
at low levels in COLO684 cells as faint bands were identified at 50 kDa (refer to 
Figure 3.3 A). subunit expression was highest at 25 nM AP, (refer to Figure 
3.3 A and B).subunit expression at 5 nM and 75 nM was moderately increased; 
at 50 nM and 2 nM there was weak expression of the  protein. However, this 
data may not be fully representative of expression as the assay exposure time 
was 24 h, and the GABAAR subunit polypeptide half-life is reported to be 25 h 
(Lyons et al., 2000).  
After the primary assay was conducted, alterations were made to increase the 
exposure time to 72 h to account for the GABAARs protein half-life.  The 
APconcentrations 2 nM and 200 nM were removed to increase accuracy of the 
assay as 200 nM is not a true representation of a physiological concentration 
(Parizek et al., 2005). COLO684 cells were treated with APconcentrations of 5 
nM, 25 nM, 50 nM, 75 nM, and 150 nM. The immunoblot appeared to have faint 
bands at 50 kDa running across the range of AP concentrations 0 nM, 5 nM, 25 
nM, 50 nM, 75 nM, and 150 nM (refer to Figure 3.3 C and D). Unspecific binding 
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of the antibody,also occurredin the secondary assay. These bands can be 
noted in all samples at approximately 80 kDa.The data taken from both assays 
shows that  subunit is expressed in the COLO684 cells but appears unaffected 
by exposure to AP at physiologically-relevant concentrations.  
 
 
 
Figure 3.3 Analysis of the effect of APon GABAA receptor  subunit 
expression. A:  expression in COLO684 cells when treated with AP 0- 200 
nM for 48 h, 30 ng loaded on a 12% gel. B: Control -actin 30 ng loaded to a 12% 
gel. C:  expression in COLO684 cells when treated with AP 0- 150 nM for 72 
h, 30 ng loaded on a 8% gel D) Control -actin 30 ng loaded to a 12% gel. 
 
3.8 AP affect on GABAAR subunit gene expression 
 
After the primary and secondary assays were conducted as described in section 
2.5, alterations were made to increase the AP exposure time to 48 h to account 
for the protein half-life. COLO684 cells were treated with 5 nM, 50 nM and 100 
nM AP. The range of APconcentration was to account for varying reports 
physiological concentrations, while also accounting for the changes in data 
obtained from the primary and secondary assays (data shown in Figure 3.3 A,B,C 
and D).  
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The GABAAR subunits analysed in COLO684 cells treated with 5 nM, 50 nM and 
100 nM APfor 48 h, were 1,2, 5, 2, 3, 3.  and  1,2, 2, 3 and  
were undetectable in COLO684 cells (refer to Table 3.3). These results are 
contradictory, as the subunitincreases receptor sensitivity to AP. The 1 
and2 subunits have also been reported to change in expression when exposed 
to AP(Brussaard et al., 1997). 
The GABAAR 5 subunit showed a decrease in expression at 5 nM, however the 
highest expression of 5 transcript appeared to occur at 50 nM APand 100 nM 
AP with both showing a 6-fold increase (refer to Figure 3.4 A). The  subunit 
was not detected in healthy or cancerous uterine samples, but it was detected in 
COLO684 cells. Following 48 h exposure to AP the data shows lowest 
expression occurring at the 100 nM, and the highest expression occurring at 50 
nM showing a 4-fold increase (refer to Figure 3.4 B). The3 subunit was also 
identified in the COLO684 cells (refer to Figure 3.4 C), which correlated with 
robust expression in the human cancerous samples. The expression profile in 
response to AP treatment was similar to both 5 and The highest expression 
of 3 subunit was at 50 nM AP showing a 3-fold increase, the lowest expression 
was noted at 5 nM AP 
ANOVA and Tukey post hoc statistical analysis tests showed no significant 
difference in treatments between DMSO, 5 nM, 50 nM and 100 nM AP. The 
primary data indicate that AP does not have an effect on the 5, and3 gene 
expression. 
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Table 3.3 Gene expression of the selected GABAAR subunits in APtreated 
COLO684 Cells. Expression of the different GABAAR subunits (n=3) was 
assessed by qRT-PCR and normalised to expression of the GAPDH and ATP5B 
reference genes. Expression represented by +: expression of GABAAR subunits; 
ND: not detected and NA: not assessed  
 
 
 
 
 
 
 
 
 
 
  
GABAAR subunits 
Expression in treated  
APCOLO684 Cells  
N3 
 ND 
 ND 
 + 
 + 
 ND 
 + 
 ND 
 ND 
 + 
 NS 
 NS 
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Figure 3.4 Change in GABAAR 5, and 3 subunit gene expression in 
COLO684 cells treated with different concentrations of AP. GABAAR 
subunit gene expression was assessed in COLO684 cells treated with 5, 50 and 
100 nM APfor 48 h via qRT-PCR and normalised to the GAPDH and ATP5B 
reference genes.  Data was expressed as a fold change in gene expression 
relative to the vehicle control (DMSO). A: 5 subunit gene; B: subunit gene; C: 
3 subunit gene.  
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3.9 AP effect on CCCs gene expression 
 
This study also looked at the possible change in expression of the CCCs to help 
identify the first evidence of a potential GABA switch/change in chloride gradient 
in uterine cells (Ganguly et al., 2001) at different AP concentrations relevant to 
the gestation period. COLO684 cells were treated with 5 nM, 50 nM and 100 nM 
AP for 48 h and analysed using qRT-PCR.  
NKCC1 (refer to Figure 3.5 A) showed a decrease in expression at 5 nM, 
however the highest expression of NKCC1 transcript appeared to occur at 50 nM 
APand 100 nM AP with both showing a 4-fold increase.  KCC1 data collected 
(refer to Figure 3.5 B) showed no change in KCC1 gene expression at 5 nM 
APwith a slight increase in expression occurring at 50 nM AP. However KCC1 
expression was noted to decrease at 100 nM. The results show KCC1 is 
expressed in COLO684 cells at low levels, and when AP is added gene 
expression is reduced, although these changes were not significant. KCC3 data 
shows varying expression when treated with AP(refer to Figure 3.5 C).The 
highest expression appear at 5 nM with a 3 fold change. High expression was 
noted at 100 APwith the lowest expression of KCC3 occurring at 5 nM. KCC4 
expression (refer to figure 3.5 D) was shown to be highly expressed at 100 nM 
with a 4 fold change, the lowest expression appears at 5 nM, however the DMSO 
shows high expression of KCC4 so is hard to determine whether it is a APor 
drug vehicle causing the effect. 
ANOVA and Tukey post hoc statistical analysis tests showed no significant 
difference in treatments between DMSO, 5 nM, 50 nM and 100 nM AP. The 
primary data indicate that AP does not have an effect on NKCC1, KCC1, KCC3 
and KCC4 gene expression. 
These initial results show that many of the GABAA receptor subunit genes and 
the CCC genes are expressed in uterine cells and that the expression of a 
number of these genes is not affected by APat physiologically-relevant 
concentrations. This provided the first evidence that during gestation, there is the 
potential for GABA receptor and CCC gene expression to be regulated in 
response to other steroid hormones.  
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Figure 3.5 Change in CCC gene expression in COLO684 cells treated with 
AP. CCC expression was assessed by qRT-PCR in COLO684 cells treated with 
5 nM, 50 nM and 100 nM APfor 24h, 48 h and 72 h. Expression was normalised 
to GAPDH and ATP5B reference genes.  Data was expressed as a fold change 
in gene expression relative to untreated control. A: NKCC1; B: KCC1; C: KCC3 
D: KCC4. 
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3.10 APα effect on GABAAR subunit protein, and CCCs protein 
expression 
 
Once the GABAAR and CCC gene expression was analysed by qRT-PCR the 
next stage of the study was to analyse the change in π protein level in APα treated 
COLO684 cells by immunoblotting. There was variation noted between the 
triplicate treated COLO684 cells with APα (refer to Figure 3.6 A). The first 
immunoblot illustrates  protein is present in untreated COLO684 cells. protein 
bands were also detected in the presence of 5 nM, 50 nM and 100 nM APas 
well as in the DMSO control and the positive control of endometrial cancer. The 
bands are, however, located at 100 kDa rather than 50 kDa indicated in the 
antibody datasheet. In the second blot (refer to Figure 3.6 B) faint bands of  
expression are detected at 5 nM, 50 nM and 100 nM AP as well as the untreated 
control, DMSO and endometrial cancer. These bands are detected at the correct 
size of 50 kDa, however unspecific binding can also be noted in all lanes at the 
42 kDa mark. The third blot (refer to Figure 3.6 C) shows  expression in 
endometrial cancer, however no other signs of the  protein at any of the times 
or APconcentrations tested. These results show that unfortunately, the 
protein data was unreliable due to varying results with the immunoblots. 
Immunoblotting with actin, indicates equal loading of the protein across the 
membrane (refer to Figure 3.6 D).  
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Figure 3.6 Analysis of the effect of AP on  protein expression in COLO684 
cells. COLO684 cells were treated with AP0-100 nM for 24 h, 48 h and 72 h 
and  protein expression was analysed by immunoblotting. Thirty micrograms of 
lysate were resolved via 8% SDS-PAGE gel and transferred to nitrocellulose. 
Three individual replicate experiments are shown (A-C). -actin immunoblot is 
shown in D. 
3.11 APaffect on CCCs protein expression 
 
The CCC protein expression was analysed using immunoblotting to identify any 
possible changes in protein expression when treated with AP.  The first CCC 
member to be analysed was NKCC1, which was expected to have a molecular 
weight of 130 kDa to 180 kDa (Santa Cruz Biotechnology, INC, Germany).  The 
initial 72 h exposure time showed expression of NKCC1 with a band detected at 
130 kDa however, there appeared to be no induction of NKCC1 with 5 nM, 25 
nM, 50 nM, 75 nM, or 150 nM AP (refer to Figure 3.7 panel 1 A,B). In the second 
replicate blot, low expression of NKCC1 was observed with a slight induction at 
72 h 5 nM and 50 nM AP(refer to Figure 3.7 panel 2 A,B).  The results show 
that NKCC1 protein expression may be affected by AP. 
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Figure 3.7 Analysis of the effect of AP on NKCC1 expression. NKCC1 
expression was analysed in COLO684 cells treated with AP 0 - 150 nM for 72 
h. Thirty micrograms of lysate were resolved via 8% SDS-PAGE gel and 
transferred to nitrocellulose. Membranes were probed with antibodies towards 
NKCC1 (panel 1 and 2, A) or β actin (panel 1 and 2, B) indicated by arrows. 
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3.11.1 AP effect on KCC3 protein expression 
 
KCC3 protein expression in COLO684 cells was also analysed. KCC3 has an 
expected molecular weight of 127 kDa and the results indicated induction of 
KCC3 protein expression at 24 h in the presence of 5 nM, 50 nM and 100 nM 
AP. KCC3 was also induced at 72 h in the presence of 5 nM, 50 nM, 100 nM 
AP (Figure 3.8 A) however induction was also observed when COLO684 cells 
were treated with DMSO (refer to Figure 3.8 A).There is also no sign of induction 
during the 48 h exposure time (Figure 3.8 A). The data indicates a change in 
KCC3 protein expression with longer exposure to AP increasing the protein 
expression. Although the antibody used does show unspecific binding to the 
membrane. The non-specific binding occurs at 150 kDa, 129 kDa and 75 kDa 
and the intensity of the unspecific bands does not appear to change depending 
on the AP concentration or the exposure time. 
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Figure 3.8 Analysis of the effect of AP on KCC3 expression. KCC3 
expression was analysed in COLO684 cells treated with 0-100 nM APfor 24 h, 
48 h and 72 h. 30 µg was loaded on a 8% SDS-PAGE and transferred to 
nitrocellulose.  Membranes were probed with antibodies towards KCC3 or β actin 
indicated by arrows. 
. 
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3.11.2 APeffect on KCC4 protein expression. 
 
KCC4 has an expected molecular weight of 100 kDa and a faint band 
representing KCC4 was detected (Figure 3.9 A). There appeared to be induction 
occurring with 100 nM APexposure for 72 h (Figure 3.9 A). The antibody used 
shows unspecific binding at 180 kDa, 130 kDa and 75 kDa. However, the intensity 
of the non-specific bands does not change depending on the AP concentration 
or the exposure time. The immunoblot data of the CCCs may show a change in 
CCC protein expression depending on the AP concentration in accordance with 
the exposure time.  
The change in protein expression potentially show that GABAARs have an 
excitatory or inhibitory effect during the gestational period however the exact 
function cannot be determined by the results of the study.   
Figure 3.9 Analysis of the effect of AP on KCC4 expression. KCC4 
expression was analysed in COLO684 cells treated with 0-100 nM AP for 24 h, 
48 h and 72 h. Thirty µg was loaded on a 8% SDS-PAGE and transferred to 
nitrocellulose.  Membranes were probed with antibodies towards KCC3 or β actin, 
indicated by arrows. 
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3.12 Analysis of  subunit expression in pregnant and non-pregnant 
sheep uterine samples 
 
The identification of -subunit expression in non-pregnant and pregnant sheep 
uterine samples was of particular interest in the current study, so  expression in 
human uterus, endometrial cancer, pregnant, non-pregnant samples and 
APtreated and untreated COLO684 cells were analysed by immunoblotting 
(Figure 3.10 A). The data clearly shows GABAAR  subunit was present in 
endometrial cancer but expression was not detected in healthy human uterus 
(Figure 3.10 A).  In the sheep uterine samples, there was potentially an increase 
in  protein expression in pregnancy (Figure 3.10 A), but this data needs to be 
confirmed.  protein expression was downregulated in the 100 nM APtreated 
cells when compared to the untreated COLO684 cells (Figure 3.10 A).  These 
preliminary results indicated that protein is expressed in pregnancy which 
supports the study hypothesis that GABAA receptors containing the  subunit may 
have a potential role in premature labour.  
 
Figure 3.10 GABAAR subunitprotein expression in pregnant and non-
pregnant sheep uterine samples. A) subunit protein expression in healthy 
human uterus, endometrial cancer, pregnant, non-pregnant samples and AP 
treated and non-treated COLO684 cells. B) Immunoblot of the control -actin. 
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3.13 Key findings in relation to the aims of the project 
 
1) GABAAR subunit expression was found in human uterus. This is the first 
study to quantitatively analyse all the relevant subunits. 
2) The subunits expressed in uterus were different to those normally 
expressed in the human brain. This is consistent with data in the literature 
about receptors found outside the CNS.  
3) The subunit expression was different in human uterine cancer. GABAAR 
are well documented to be expressed in different cancers, but their role is 
unclear. 
4) The π subunit, which is the one we are interested in as it confers APα 
sensitivity to the receptor is robustly expressed in uterus and uterine 
cancer. 
5) This is the first study that has also looked at CCC expression, alongside 
GABAAR expression. Selected CCC genes are expressed in human uterus 
and the expression profile changes in cancer. 
6) GABAAR π subunit protein is expressed in sheep pregnancy samples.  
This is consistent with data in the literature about π in pregnancy. 
7) In vitro model was developed using COLO684 cell line to analyse GABAAR 
and CCCs expression in the presence of APα. 
8) GABAAR subunits expression changes with APα. These results are 
consistent with the literature data. 
9) Selected CCC expression changes with APα. T`his is the first study to 
quantitatively analyse all CCC and the effect with APα. 
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In this study we hypothesise that a lack, or a change in phenotype/ activity 
of GABAAR subtype might induce preterm contraction, to prove or disprove 
the hypothesis certain aims were set out. To identify the difference in 
GABAAR subunit and CCC expression in healthy human uterus and 
human endometrial cancer, pregnant and non pregnant sheep samples 
and treated APα COLO684 cell line were used. The results of the study 
show that GABAAR subunit and CCC are expressed in human uterus and 
endometrial cancer with the expression pattern of GABAAR subunit and 
CCC changing in endometrial cancer. This supports, but does not prove 
the hypothesis as it shows a possible change in the GABAAR subtype in 
the diseased sample which is exposed to the same hormone as the 
pregnant uterus. This supports the hypotheses that a change in 
phenotype/ activity might induce preterm contraction. The data gathered 
from the sheep samples show that the GABAAR  subunit was expressed 
in pregnant and non pregnant uteri, however no major changes could be 
confirmed. The data does however support the hypothesis by showing that 
GABAAR  subunit is expressed in pregnancy and a change in the 
expression of the GABAAR  subunit may induce preterm contraction. The 
COLO684 cells when treated with APshowed no expression of the 
GABAAR subunit however other subunits were expressed. COLO684 
cell line may not be expressing the GABAAR subunits in a similar fashion 
as a result of the cells becoming immortalised. This data does not confirm 
nor deny the study hypothesis but shows support, as it proves that 
potentially a different GABAAR subtype with a different function is present 
in the endometrium. 
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Chapter 4 Discussion 
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